Fore Bio Clears Interim Review in BRAF Fusion Cancer Study
PHILADELPHIA, PA — Fore Biotherapeutics will continue its FORTE study of plixorafenib as planned after an independent monitoring committee cleared the first interim efficacy analysis of its BRAF fusion cohort, …
Fore Bio Clears Interim Review in BRAF Fusion Cancer Study Read More